QQQ
-7.56
406.32
-1.9%
BTC/USD
-4519.72
54440.64
-7.67%
DIA
-8.82
366.85
-2.46%
SPY
-10.05
479.49
-2.14%
TLT
+ 3.71
143.11
+ 2.53%
GLD
-0.24
167.36
-0.14%

Aurora Cannabis Analyst Lifts Price Target As Company Nears German Regulatory Approval

April 8, 2019 12:08 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Aurora Cannabis Inc. (NYSE:ACB) is close to being awarded the maximum number of lots for domestic cannabis production in Germany. The deal's completion is subject to the finalization of an appeals process next week; Canaccord Genuity considers the process a moderate-to-high risk.

The Analyst

Matt Bottomley maintained a Speculative Buy rating on Aurora and raised the price target from CA$13 ($9.76) to CA$13.50 ($10.13).

The Thesis

The market potential in Germany could translate to long-term upside, according to Bottomley.

Germany's peak medical demand is double Canada's, with growing public acceptance and high reimbursement expected.

"We believe Aurora's receipt of this license adds incremental legitimacy to the overall international optionality secured by the company as of late," Bottomley wrote in a note.

The Cannabis Capital Conference is coming back to Toronto! Click here to learn how you can join Tim Seymour, Jon Najarian and many others.

Aurora made an impressive early start in Canada's adult use market, reporting recreational weed sales of CA$21.6 million in the second quarter, or 20-percent market share, Bottomley said. The company's sales volumes imply that Aurora earned a gross price of more than CA$6 per gram of dried flower and more than CA$10 per gram of oil, he said. If accurate, both figures exceed Cannacord's expectations.

The analyst also mentioned Aurora's multiple acquisitions in recent years, advising investors to keep a close eye on the integration of these products in future sales quarters.

Price Action

Aurora's stock traded around $9.04 at time of publication, down 1.4 percent.

Related Links:

Aphria, Aurora Cannabis, Wayland Group Win Public Tender To Grow Medical Marijuana In Germany

Aurora Cannabis Files Preliminary Prospectus To Raise Up To $750M

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

What Are The Value Drivers For Aurora Cannabis? Analyst Opines Post Q1 Earnings

What Are The Value Drivers For Aurora Cannabis? Analyst Opines Post Q1 Earnings

After the market closed on Tuesday, Aurora Cannabis Inc. (NYSE: ACB) disclosed its financial and operational results for the first quarter of fiscal 2022. read more
What Will Drive Aurora Cannabis' Value Most? Analyst's Thoughts Ahead Of Q1 Earnings Report

What Will Drive Aurora Cannabis' Value Most? Analyst's Thoughts Ahead Of Q1 Earnings Report

Over the last year, Aurora Cannabis Inc. read more
Piper Sandler's Michael Lavery Shares Cannabis Industry Projections, Names 'The Real Key Catalyst To Watch'

Piper Sandler's Michael Lavery Shares Cannabis Industry Projections, Names 'The Real Key Catalyst To Watch'

The U.S. cannabis market has the potential to reach $115 billion by 2030, while last year regulated sales in the country have hit $17.5 billion, according to Michael Lavery, a director and senior research analyst covering consumer staples and cannabis for Piper Sandler. read more
Is Aurora Cannabis' 'Business Transformation Plan' Yielding Results?

Is Aurora Cannabis' 'Business Transformation Plan' Yielding Results?

Aurora Cannabis (NASDAQ: ACB) (TSX: ACB) reported a 45% year-over-year plunge in consumer cannabis net revenue, while its total net revenue in the fourth quarte read more